Top Markets
#1 PulseChain PulseChain +45.01%
#2 RedStone RedStone +16.75%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.64%
#4 Meteora Meteora +9.03%
#5 SkyAI SkyAI +8.73%
#6 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +8.09%
#7 Unit Pump Unit Pump +7.79%
#8 Pump.fun Pump.fun +7.79%
#9 Lighter Lighter +7.66%
#10 Lista DAO Lista DAO +7.22%
Coin of the day
PulseChain PulseChain
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Angion Biomedica Corp. Angion Biomedica Corp.

Angion Biomedica Corp.

ANGN
Rang in Aktien #27858
Angion Biomedica Corp. operates as a biopharmaceutical enterprise,... Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale, New York.
Aktienkurs
$1.00
Zuletzt synchronisiert: 2023-06-01
Marktkapitalisierung
$30.11M
Veränderung (1 Tag)
2.04%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Angion Biomedica Corp. (ANGN)

Kategorie

Healthcare
P/B-Verhältnis für Angion Biomedica Corp. (ANGN)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Angion Biomedica Corp. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Angion Biomedica Corp. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH